Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | 4332 | Peak area | HAHA | IFN-G |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | BS4 | IFN-G | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | BS4 | IL-17A | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | BS4 | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | BS4 | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | BS4 | Untreated | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | HAHA | IL-17A | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | HAHA | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | HAHA | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | HAHA | Untreated | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | PAK | IFN-G | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | PAK | IL-17A | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | PAK | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | PAK | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M-H)- | Peak area | PAK | Untreated | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 1706 | Peak area | BS4 | TNF-alpha |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 2565 | Peak area | PAK | IL-17A |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 2567 | Peak area | BS4 | IFN-G |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 3175 | Peak area | PAK | IFN-G |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 3322 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 4271 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | 8134 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | BS4 | IL-17A | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | BS4 | Untreated | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | HAHA | IFN-G | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | HAHA | IL-17A | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | HAHA | TNF-alpha | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | PAK | TNF-alpha | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | PAK | TNF-alpha+IL-17A | |
Reversed phase POSITIVE ION MODE | 4-HYDROXYPHENYLACETATE (CAS# 156-38-7); (M+H)+ | Peak area | PAK | Untreated |